Ulisse Biomed Past Earnings Performance
Past criteria checks 0/6
Ulisse Biomed's earnings have been declining at an average annual rate of -72.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 40.1% per year.
Key information
-72.1%
Earnings growth rate
-38.2%
EPS growth rate
| Biotechs Industry Growth | 14.8% |
| Revenue growth rate | -40.1% |
| Return on equity | -28.2% |
| Net Margin | -1,655.1% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Ulisse Biomed makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -7 | 2 | 0 |
| 31 Mar 24 | 0 | -6 | 1 | 0 |
| 31 Dec 23 | 0 | -5 | 1 | 0 |
| 30 Sep 23 | 0 | -3 | 1 | 0 |
| 30 Jun 23 | 0 | -2 | 1 | 0 |
| 31 Mar 23 | 0 | -1 | 0 | 0 |
| 31 Dec 22 | 0 | -1 | 0 | 0 |
| 30 Sep 22 | 0 | -1 | 0 | 0 |
| 30 Jun 22 | 0 | -1 | 0 | 0 |
| 31 Mar 22 | 0 | -1 | 0 | 0 |
| 31 Dec 21 | 0 | -1 | 0 | 0 |
| 30 Sep 21 | 0 | 0 | 0 | 0 |
| 30 Jun 21 | 1 | 0 | 0 | 0 |
| 31 Mar 21 | 1 | 0 | 0 | 0 |
| 31 Dec 20 | 1 | 0 | 0 | 0 |
| 31 Dec 19 | 0 | -1 | 1 | 0 |
| 31 Dec 18 | 0 | -2 | 1 | 0 |
Quality Earnings: UBM is currently unprofitable.
Growing Profit Margin: UBM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: UBM is unprofitable, and losses have increased over the past 5 years at a rate of 72.1% per year.
Accelerating Growth: Unable to compare UBM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: UBM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-21.2%).
Return on Equity
High ROE: UBM has a negative Return on Equity (-28.16%), as it is currently unprofitable.